Abstract
Aim:
To study the distribution of [131I]-labeled anti-CEA MoAbs and its therapeutic effect on the human colonic cancer model in nude mice.
Methods:
A nude mice model of human colonic cancer was established. [131I]-labeled anti-CEA MoAbs were injected intravenously into mice. The distribution of the MoAbs was then determined and the effect of RIT on human colonic cancer was observed.
Results:
The [131I]-labeled anti-CEA MoAbs had a specific distribution after injection. Tumor/ non-tumor ratios for [131I]-labeled anti-CEA MoAbs were 10–20 times higher than [131I]-labeled IgG 96 h after injection. Thirty days after injection, significant inhibition of the volume and weight of tumor was observed in the treated mice compared with the control. The tumor growth inhibition rate of 3.1 mCi/kg CEA MoAbs group (LS180, LS174T, SW1116) was 47.8%–64.0%. This was 69.6%–78.6% in the 6.25 mCi/kg CEA MoAbs group, and 81.8%–86.2% in the 12.5 mCi/kg [131I]- labeled anti-CEA MoAbs group. The plasma CEA level was also lower in treated mice.
Conclusion:
The results indicate that [131I]-labeled anti-CEA MoAbs can be effective in RIT on colonic cancers.
Similar content being viewed by others
Article PDF
References
Debinski W, Karlsson B, Lindholm L, Siegall CB, Willingham MC, FitzGerald D, et al. Monoclonal antibody C242-Pseudomo-nas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J Clin Invest 1992; 90: 405–11.
Ditzel HJ, Garrigues U, Andersen CB, Larsen MK, Garrigues HJ, Svejgaard A, et al. Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc Natl Acad Sci USA 1997; 94: 8110–5.
Philben VJ, Jakowatz JG, Beatty BG, Vlahos WG, Paxton RJ, Williams LE, et al. The effect of tumor CEA content and tumor size on tissue uptake of indium 111-labeled anti-CEA monoclonal antibody. Cancer 1986; 57: 571–6.
Buchegger F, Pfister C, Fournier K, Prevel F, Schreyer M, Carrel S, et al. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. J Clin Invest 1989; 83: 1449–56.
Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T . Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci USA 1991; 88: 9287–91.
Han JS, Nair PP . Flow cytometric identification of cell surface markers on cultured human colonic cell lines using monoclonal antibodies. Cancer 1995; 76: 195–200.
Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000; 60: 4475–84.
Buchegger F, Mach JP, Pèlegrin A, Gillet M, Vogel CA, Buclin T, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995; 36: 420–9.
Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2002; 2: 31–42.
Zhu H, Baxter LT, Jain RK . Potential and limitations of radio-immunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997; 38: 731–41.
Ychou M, Pèlegrin A, Faurous P, Robert B, Saccavini JC, Guerreau D, et al. Phase I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer 1998; 75: 615–9.
Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, et al. Complete tumor ablation with iodine 131-radio-labeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 1986; 77: 739–45.
Denardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997; 17: 1745–51.
Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 2003; 44: 2000–18.
Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003; 9: 5842–52.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lu, Qj., Bian, Gx., Chen, Yy. et al. Radioimmunotherapy of carcinoma of colon with [131I]- labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen. Acta Pharmacol Sin 26, 1259–1264 (2005). https://doi.org/10.1111/j.1745-7254.2005.00177.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00177.x